122 related articles for article (PubMed ID: 38916742)
1. Efficacy and safety of ruxolitinib in the treatment of chronic graft-versus-host disease: a retrospective analysis.
Denk A; Mittermaier C; Weber D; Fante M; Güneş S; Edinger M; Herr W; Wolff D
Ann Hematol; 2024 Jun; ():. PubMed ID: 38916742
[TBL] [Abstract][Full Text] [Related]
2. Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis.
Denk A; Edinger M; Weber D; Holler E; Fante M; Meedt E; Gunes S; Poeck H; Mittermaier C; Herr W; Wolff D
Ann Hematol; 2024 Jun; ():. PubMed ID: 38916740
[TBL] [Abstract][Full Text] [Related]
3. A Multicenter, Retrospective Study Evaluating Clinical Outcomes of Ruxolitinib Therapy In Heavily Pretreated Chronic GVHD Patients With Steroid Failure.
White J; Elemary M; Linn SM; Novitzky-Basso I; Culos S; Tan SK; Kelly K; Deotare U; Xenocostas A; Hamad N; Law A; Kumar R; Kim DDH
Transplant Cell Ther; 2023 Feb; 29(2):120.e1-120.e9. PubMed ID: 36460202
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation.
Wu H; Shi J; Luo Y; Tan Y; Zhang M; Lai X; Yu J; Liu L; Fu H; Huang H; Zhao Y
JAMA Netw Open; 2021 Jan; 4(1):e2034750. PubMed ID: 33502484
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Follow-Up of Ruxolitinib in the Treatment of Steroid-Refractory Chronic Graft-versus-Host Disease.
Ferreira AM; Szor RS; Molla VC; Seiwald MC; de Moraes PA; da Fonseca ARBM; Xavier EM; Serpa MG; Tucunduva L; Novis Y; Arrais-Rodrigues C
Transplant Cell Ther; 2021 Sep; 27(9):777.e1-777.e6. PubMed ID: 34118469
[TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide for salvage therapy of chronic graft-versus-host disease: a retrospective analysis.
Fante MA; Holler B; Weber D; Angstwurm K; Bergler T; Holler E; Edinger M; Herr W; Wertheimer T; Wolff D
Ann Hematol; 2020 Sep; 99(9):2181-2190. PubMed ID: 32715339
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy and safety of ruxolitinib in the salvage treatment of chronic graft versus-host disease].
Ji YP; Tang BL; Zhu XY; Liu HL; Song KD; Wan X; Yao W; Sun GY; Wang J; Sun ZM
Zhonghua Yi Xue Za Zhi; 2020 Apr; 100(16):1235-1239. PubMed ID: 32344495
[No Abstract] [Full Text] [Related]
8. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.
Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
Front Immunol; 2021; 12():673636. PubMed ID: 34276662
[TBL] [Abstract][Full Text] [Related]
9. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D
Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584
[TBL] [Abstract][Full Text] [Related]
10. Ruxolitinib in the management of steroid-resistant/-dependent acute and chronic graft-versus-host disease: results of routine practice in an academic centre.
Leung GMK; Sim JPY; Hwang YY; Chan TSY; Lie AKW; Tse E; Kwong YL
Ann Hematol; 2022 Jan; 101(1):155-163. PubMed ID: 34767056
[TBL] [Abstract][Full Text] [Related]
11. Ruxolitinib add-on in corticosteroid-refractory graft-
Dang SH; Liu Q; Xie R; Shen N; Zhou S; Shi W; Liu W; Zou P; You Y; Zhong ZD
World J Clin Cases; 2020 Mar; 8(6):1065-1073. PubMed ID: 32258077
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib in children with steroid-refractory acute graft-versus-host disease: A retrospective multicenter study of the pediatric group of SFGM-TC.
Laisne L; Neven B; Dalle JH; Galambrun C; Esvan M; Renard C; Rialland F; Sirvent A; Gandemer V;
Pediatr Blood Cancer; 2020 Sep; 67(9):e28233. PubMed ID: 32614145
[TBL] [Abstract][Full Text] [Related]
13. The Effectiveness of Ruxolitinib for Acute/Chronic Graft-versus-Host Disease in Children: A Retrospective Study.
Yang W; Zhu G; Qin M; Li Z; Wang B; Yang J; Wang T
Drug Des Devel Ther; 2021; 15():743-752. PubMed ID: 33654380
[TBL] [Abstract][Full Text] [Related]
14. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915
[TBL] [Abstract][Full Text] [Related]
15. Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience.
Xue E; Lorentino F; Pavesi F; Assanelli A; Peccatori J; Bernardi M; Corti C; Ciceri F; Lupo Stanghellini MT
Leuk Res; 2021 Oct; 109():106642. PubMed ID: 34157510
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.
Mozo Y; Bueno D; Sisinni L; Fernández-Arroyo A; Rosich B; Martínez AP; Benítez-Carabante MI; Alonso L; Uría ML; Heredia CD; Mestre-Duran C; Pascual CFB; Torres J; Losantos I; Escudero A; Ruz-Caracuel B
Pediatr Hematol Oncol; 2021 May; 38(4):331-345. PubMed ID: 33661711
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Ruxolitinib in Steroid-Refractory/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges.
Redondo S; Esquirol A; Novelli S; Caballero AC; Garrido A; Oñate G; López J; Moreno C; Saavedra SD; Granell M; Briones J; Sierra J; Martino R; García-Cadenas I
Transplant Cell Ther; 2022 Jan; 28(1):43.e1-43.e5. PubMed ID: 34757054
[TBL] [Abstract][Full Text] [Related]
18. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience.
Chin KK; Kim HT; Inyang EA; Ho V; Koreth J; Romee R; Gooptu M; Shapiro R; Antin J; Soiffer R; Jaglowski S; Pidala J; Cutler C
Transplant Cell Ther; 2021 Dec; 27(12):990.e1-990.e7. PubMed ID: 34481113
[TBL] [Abstract][Full Text] [Related]
20. FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy.
Le RQ; Wang X; Zhang H; Li H; Przepiorka D; Vallejo J; Leong R; Ma L; Goldberg KB; Pazdur R; Theoret MR; De Claro A
Oncologist; 2022 Jun; 27(6):493-500. PubMed ID: 35363318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
